Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Blood eosinophil count (BEC), immunoglobulin (Ig) E, and fractional exhaled nitric oxide (FeNO) are key clinical indicators for identifying type 2 (T2) asthma.
Objective: To provide optimal cutoff points of T2 markers for assessing T2-high or uncontrolled asthma in real-world practice.
Methods: Various clinical and laboratory parameters were analyzed according to the result of T2 markers (BEC, serum-free IgE, and FeNO) in adults with asthma who had maintained antiasthmatic medications. The cutoff levels for representing uncontrolled asthma were determined using receiver operating characteristic analysis. Blood levels of periostin and eosinophil-derived neurotoxin were measured by enzyme-linked immunosorbent assay. Activation markers of circulating eosinophils (Siglec8+) and neutrophils (CD66+) were analyzed by flow cytometry.
Results: Of 133 patients with asthma, 23 (17.3%) had 3 T2 markers (BEC ≥ 300 cells/μL, serum-free IgE ≥ 120 ng/mL, and FeNO ≥ 25 parts per billion) and significantly higher levels of sputum eosinophils, blood eosinophil-derived neurotoxin, and Siglec8+ eosinophils but lower 1-second forced expiratory volume percentage, in addition to a higher rate of uncontrolled status (P < .05 for all). Furthermore, patients with uncontrolled asthma had significantly higher levels of FeNO and BEC with lower 1-second forced expiratory volume percentage (P < .05 for all). The optimal cutoff values for predicting uncontrolled asthma were found to be 22 parts per billion of FeNO levels, 161.4 cells/L of BECs, and 85.9 ng/mL of serum-free IgE levels.
Conclusion: We suggest the optimal cutoff values of BEC, IgE, and FeNO for classifying T2-high or uncontrolled asthma, which could be applied as candidate biomarkers for targeting patients with asthma who require T2 biologics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anai.2023.05.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
One-year efficacy of Dupilumab in sense of smell, nasal polyp score and quality of life in CRSwNP patients: A real-world multicenter study in Brazil.
Braz J Otorhinolaryngol
September 2025
Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo, São Paulo, SP, Brazil.
Introduction: Chronic rhinosinusitis with nasal polyp (CRSwNP) is a predominant type 2 inflammatory disease, affecting the sense of smell and quality of life. Loss of smell compromises physical and emotional health, creating negative impacts and its treatment in CRSwNP is challenging.
Aim: To present the outcomes of dupilumab in olfactory function, Nasal Polyp Score (NPS) and quality of life in Brazilian patients with severe CRSwNP.
Three Biologic-Naïve Patients with Allergic Bronchopulmonary Aspergillosis Showing Significant Clinical Improvement with Tezepelumab.
J Asthma Allergy
August 2025
Division of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
Allergic bronchopulmonary aspergillosis is characterized by hypersensitivity to spp. and often causes intractable asthma. Studies have been conducted on biologics administered to patients with allergic bronchopulmonary aspergillosis; however, treatment may not always be successful.
View Article and Find Full Text PDFResponse to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach.
J Allergy Clin Immunol Pract
September 2025
Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care Global, Cambridge, UK; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. Electronic address:
Background: Asthma with low levels of T2-biomarkers is poorly understood.
Objective: To characterize severe asthma phenotypes and compare pre- to post-biologic change in asthma outcomes along a gradient of T2-involvement.
Methods: This was a registry-based, cohort study including data from 24 countries.
[Transcriptomic expression profile characteristics of nasal polyps with uncontrolled disease after endoscopic sinus surgery].
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
August 2025
Department of Otolaryngology, the Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, China.
To investigate the transcriptomic signature of refractory nasal polyps (NP) after endoscopic sinus surgery. Tissue samples were collected from 36 patients with NP who underwent endoscopic sinus surgery at the Seventh Affiliated Hospital of Sun Yat-sen University and the First Affiliated Hospital of Sun Yat-sen University from January 2020 to December 2021. Raw sequencing data of normal nasal mucosa samples were downloaded from publicly available GEO database (Accession Number: GSE136825).
View Article and Find Full Text PDFInfluence of ADRB2 variants on bronchodilator response and asthma control in a mixed population.
J Bras Pneumol
August 2025
. Departamento de Biorregulação, Laboratório de Imunofarmacologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador (BA) Brasil.
Objective: Given that b2 agonists constitute the primary treatment for asthma and that treatment response varies as a result of polymorphisms in the ADRB2 gene, we sought to investigate the associations between ADRB2 gene variants and bronchodilator response (BDR) in asthma patients.
Methods: A genetic database comprising 813 individuals was analyzed for variants in the ADRB2 gene. A longitudinal analysis of severe asthma patients was performed to evaluate changes in BDR over time.